Skip to main content

Table 4 Association of alphaB-crystallin with clinicopathological parameters

From: alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies

 

alphaB-crystallin

 

Negative

Weakly positive

Strongly positive

p-value (Pearson chi-square)

 

N (%)

N (%)

N (%)

 

Randomization arm

   

0.556

 E-T-CMF

367 (47.7)

55 (55.6)

32 (45.1)

 

 E-CMF

126 (16.4)

8 (8.1)

13 (18.3)

 

 ET-CMF

277 (36.0)

36 (36.4)

26 (36.6)

 

Age

   

0.058

 <50

301 (39.1)

47 (47.5)

33 (46.5)

 

 ≥50

469 (60.9)

52 (52.5)

38 (53.5)

 

Menopausal status

   

0.402

 Premenopausal

351 (45.6)

51 (51.5)

33 (46.5)

 

 Postmenopausal

419 (54.4)

48 (48.5)

38 (53.5)

 

Type of surgery

   

<0.001

 MRM

548 (71.2)

53 (53.5)

43 (60.6)

 

 Breast conserving

222 (28.8)

46 (46.5)

28 (39.4)

 

Tumor size (cm)

   

0.937

 ≤2

232 (30.1)

35 (35.4)

21 (29.6)

 

 2.1-5

435 (56.5)

55 (55.6)

40 (56.3)

 

 >5

    

Histological type

   

0.084

 Ductal

586 (76.1)

80 (80.8)

61 (85.9)

 

 Lobular

89 (11.6)

6 (6.1)

2 (2.8)

 

 Mixed

59 (7.7)

10 (10.1)

3 (4.2)

 

 Other

36 (4.7)

3 (3.0)

5 (7.0)

 

Number of positive nodes

   

0.957

 0-3

298 (38.7)

36 (36.4)

29 (40.8)

 

 ≥4

472 (61.3)

63 (63.6)

42 (59.2)

 

Histological grade

   

<0.001

 I-II

406 (52.7)

40 (40.4)

24 (33.8)

 

 III-Undifferentiated

364 (47.3)

59 (59.6)

47 (66.2)

 
  1. N, number; E, epirubicin; T, paxlitaxel; C, cyclophosphamide; M, methotrexate; F, 5-FU; MRM, modified radical mastectomy.
  2. Significant p-values are shown in bold.